跳至主要内容
临床试验/ACTRN12620000070932
ACTRN12620000070932已完成1 期

Cannabidiol (CBD) treatment for insomnia: a three-week randomised controlled pilot trial

Swinburne University of Technology0 个研究点目标入组 30 人开始时间: 2020年1月29日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • 1.Males and Females Aged 18-45 years
  • 2.Insomnia Severity Index (ISI) score of 15 or more.
  • 3.Self-report difficulties falling and / or staying asleep (yes)
  • 4.Dissatisfaction with current sleep patterns (yes)
  • 5.Sleep problems interfering with daily life (yes)

排除标准

  • 1. Inability to speak or read English
  • 2. Current shift worker
  • 3. History of severe neurological, cardiac, endocrine, gastrointestinal, or bleeding disorders (self-report)
  • 4. History of major psychiatric disorder in the past 12 months except clinically-managed mild depression
  • 5. Severe current depression (BDI score of greater than or equal to 20)
  • 6. Severe current anxiety (BAI score greater than or equal to 16)
  • 7. Pregnancy or lactation - males and females shall be advised to use reliable contraception for the duration of drug therapy and a urine pregnancy test will be performed for female participants where necessary.
  • 8. Use of any CNS-active drugs (including antidepressants, opioids, benzodiazepines) for the past 3 months or at the medical officer’s discretion
  • 9. Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia
  • 10. Other pre-existing sleep disorder (restless legs syndrome, narcolepsy, parasomnias etc.) (self-report)
  • 11. Used any modality of treatment for insomnia, including CBT, within 3 months before screening or at the medical doctor's discretion
  • 12. History of drug or alcohol dependency or abuse within approximately the past 2 years (self-report and at medical officer’s discretion)
  • 13. Probable moderate to severe obstructive sleep apnoea (STOP-BANG questionnaire)
  • 14. Currently participating in any other trials involving investigational or marketed products within 30 days prior to the screening visit.
  • 15. Not willing to abstain from driving, riding, operating heavy machinery for 8 hours after taking the nightly treatment.

研究者

相似试验